[PRESSWIRE] Parma, Italy - 05 May, 2021 -- One in ten adults in Europe suffer from reduced kidney function and yet many will be unaware of this. What is fatal is that the loss of kidney function cannot be reversed. It is therefore essential that the general public are made aware of the importance of the kidneys and how to protect them.

[PRESSWIRE] Austria - 04 May, 2021 -- CEBINA GmbH, an Austrian biotech company, today announces that azelastine, previously identified as a potential anti-COVID-19 drug, is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus. Azelastine is available as an anti-allergy nasal spray and is currently being tested in a Phase 2 efficacy trial for the treatment of early-stage COVID-19 disease.

[PRESSWIRE] Vienna, Austria - 17 February, 2021 -- In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts around the world are focusing on identifying new anti-COVID therapeutics that includes re-evaluation of existing product portfolios with a view to re-purpose drugs that have antiviral properties.

[PRESSWIRE] Denmark – 14 December, 2020 -- Many challenges are associated with the conventional eye drop bottle. The global ophthalmic industry has long pushed for a way to better deliver medication to the eye. Now, the Danish-based MedTech start-up, EYE-GO, has the solution that can improve the lives of millions of people globally suffering from dry eyes and other chronic eye conditions. Leading ophthalmologists and frontrunning international players in the industry have already named it “a true game-changer in eye care”. The Danish state participated in the latest funding round.

[PRESSWIRE] Austria - 19.11.20 -- Eveliqure Biotechnologies GmbH, a clinical-stage biotechnology company, today announces the publication of preclinical data with ShigETEC, its vaccine candidate against Shigellae and Enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines8040689).

[PRESSWIRE] Austria - 24 September, 2020 -- Eveliqure Biotechnologies GmbH, an Austrian biotechnology company, today announces the initiation of clinical testing for its ShigETEC vaccine candidate, with the dosing of the first subject in a Phase 1 safety and immunogenicity study in Europe.

[PRESSWIRE] US - 19 September, 2020 - B Medical Systems, a leading European medical refrigeration and global vaccine cold chain manufacturer, is pleased to announce the official opening of its new 10,000 sq ft sales office and warehouse in Noblesville, Indiana. With over 40 years of experience in the medical refrigeration and vaccine cold chain market, the company offers a full line of medical-grade refrigerators, freezers, ultra-low temperature freezers, and transport devices designed for the safe storage and transport of biological materials, critical samples, blood, and vaccines.

[PRESSWIRE] Israel - 13 August, 2020 -- Kanabo Research LTD und Simply Green BV haben eine exklusive Vertriebsvereinbarung unterzeichnet, um die medizinische Verdampfungstechnologie von Kanabo auf den deutschen Markt zu bringen. Im Rahmen der Vereinbarung erhält Simply Green das exklusive Vertriebsrecht für die proprietäre Lieferplattform Kanabo VapePod® und Rezepturen über dessen Vertriebsnetz.

[PRESSWIRE] London, United Kingdom - 13 August, 2020 -- Global liquidation specialists Maynards Europe and Liquidity Services are to sell the complete contents of Recipharm’s Ashton-under-Lyme pharmaceutical facility by online auction on October 22. The project will include logistics partners offering turnkey solutions to relocate and recommission equipment globally.

[PRESSWIRE] Vienna - 30th June 2020 -- Eveliqure Biotechnologies today announces that further financing has been secured from Arax Capital Partners comprising the last instalment of a €1.7M total investment provided by Arax. This is complemented by further private investment from Baobá and a Swiss based family office, and totals around €0.5M.